Cystic fibrosis is associated with increased sodium absorption, reduced chloride conductance, and an increased potential difference across the respiratory epithelium."2 These abnormalities may contribute to the pathogenesis of the disease by reducing the water content of the airway surface liquid,' thus impairing mucociliary clearance. Topically applied amiloride blocks entry of sodium into respiratory epithelial cells and reduces the potential difference of the airway epithelium towards normal in patients with cystic fibrosis.
This may improve the hydration of the surface liquid.4 Preliminary evidence from patients with cystic fibrosis suggests that nebulised amiloride reduces sputum viscosity and elasticity and produces transient improvements in the clearance of sputum by mucociliary mechanisms and by coughing,5 and that regular inhalation reduces the rate of deterioration in forced vital capacity. 6 The efficacy of nebulised amiloride will depend on the delivery of sufficient quantities of the drug to the airway surface. In sheep the effects of amiloride on the potential difference of the airway epithelium are dose related, maximal effects occurring at high airway surface liquid concentrations;7 the drug is then cleared rapidly from this site, resulting in a short duration of action.78 A high initial airway surface concentration of amiloride is therefore likely to be needed to maintain a therapeutic effect between inhalations, and this will require an efficient method of aerosol administration.
In this study we compared the pulmonary deposition of amiloride nebulised from two apparently suitable nebuliser systems.7 The aim of the study was to determine how much amiloride was delivered to the lungs from each system and which nebuliser would be more suitable for use in clinical trials of amiloride.
Methods

NEBULISERS
The nebulisers selected for the study were System 22 Acorn (Medic-Aid Ltd), a jet nebuliser driven by an air compressor (CR 60, Medic-Aid Ltd) in common use for delivery of nebulised antibiotics, and Fisoneb (Fisons/ Medix), a portable hand held ultrasonic nebuliser. Minor modification of the Fisoneb mouthpieces was needed so that a filter could be fitted over the expiratory port to prevent escape of radiolabelled aerosol (additional deadspace 15 ml). The Fisoneb was run at its midpoint setting.
VALIDATION OF THE AMILORIDE MARKER
In the absence of a suitable radiolabelled amiloride analogue, an indirect marker (99mTc colloidal human serum albumin (99mTc HSA, Venticoll)) had to be used to estimate deposition of amiloride in the lung. For this approach to be valid the marker should not affect the mass output of nebulised amiloride or the particle size output of the nebuliser, and it should be distributed in the aerosol cloud like amiloride. This was assessed by measuring the mass output of the System 22 Acorn nebuliser by nebulising amiloride solution to dryness in the presence and absence of 99mTc HSA and capturing the aerosol cloud by means of a preimpinger and filter. A similar study was not performed for the Fisoneb nebuliser as the output of ultrasonic nebulisers is underestimated if measured without a subject breathing from the mouthpiece. The amiloride content of washings from the preimpinger and filter (cloud recovery) and nebuliser was measured by spectrophotometry (361 nm). The particle size of the output of amiloride solution from both nebulisers was measured in the presence and absence of QQmTc HSA with a Malvern Master laser particle sizer. An amiloride solution containing 99mTc HSA was nebulised and the cloud sampled with a nine stage cascade impactor. Activities associated with filters from each stage of the cascade impactor (representing particles of different size ranges) were compared with the concentrations of amiloride in washings from these filters. The amiloride content of the filters was determined by gradient high pressure liquid chromatography, 01% trifluoroacetic acid in water and 0-1% trifluoroacetic acid in acetonitrile being used. With a flow rate of 2 ml/min amiloride was eluted as a sharp peak at 3-4 minutes, and there was a linear relation between amiloride content and the amiloride peak integral. The mean extraction efficiency of amiloride from the filters was 55% (SD 5%) and was independent of the initial loading concentration.
MEASUREMENT OF PULMONARY AMILORIDE DEPOSITION
Eight adults (six male, two female) with cystic fibrosis volunteered to take part and each gave written informed consent. The study was approved by the ethics committees of the West Lambeth Health District and the Royal Brompton and National Heart Hospital. Each subject was studied on two occasions, with the System 22 on one occasion and Fisoneb on the other. Nebulisers were allocated in random order. Before aerosol inhalation dynamic (five second counting frames) xenon-133 ventilation scanning was performed during breath holding, at equilibrium, and during washout for measurement of total and regional ventila- Dynamic lung scans performed during aerosol inhalation (fig 3) showed that deposition of amiloride occurred more rapidly and was completed sooner with the Fisoneb nebuliser (4-5 minutes) than with System 22 nebuliser (6-7 minutes). The total amount of amiloride deposited at the end of the inhalation period was greater with the Fisoneb than with the System 22 nebuliser and this was the case for all lung regions (table 2) , especially the central and upper zones. The ratio of central to peripheral deposition (corrected for volume differences on the basis of the "'Xe counts from each region) did not differ significantly between the two nebulisers (table 2), but deposition ofamiloride in the oropharynx and stomach was greater with the Fisoneb nebuliser (table 2). FEV,, FVC, and PEF did not change significantly after amiloride inhalation with either nebuliser (table 3) , and no adverse effects of the inhalations were reported by the patients. The patients preferred the Fisoneb because it was less noisy than the CR 60 compressor used with System 22.
Discussion
In this study we compared the pulmonary deposition of amiloride when given via two apparently suitable nebulisers. These were selected because desirable features of nebul- 
